Free Trial
→ What Steve Bannon revealed about Trump’s gold play (From Reagan Gold Group) (Ad)tc pixel Free GMAB Stock Alerts

Genmab A/S (GMAB) Stock Forecast & Price Target

Genmab A/S logo
$26.94 +1.06 (+4.07%)
As of 03:31 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
Compare

Genmab A/S - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Moderate Buy
Based on 11 Analyst Ratings
Sell
1
Hold
3
Buy
7

Based on 11 Wall Street analysts who have issued ratings for Genmab A/S in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 11 analysts, 1 has given a sell rating, 3 have given a hold rating, 6 have given a buy rating, and 1 has given a strong buy rating for GMAB.

Consensus Price Target

$37.60
39.54% Upside
According to the 11 analysts' twelve-month price targets for Genmab A/S, the average price target is $37.60. The highest price target for GMAB is $48.00, while the lowest price target for GMAB is $27.00. The average price target represents a forecasted upside of 39.54% from the current price of $26.95.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for GMAB and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Genmab A/S and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

GMAB Analyst Ratings Over Time

TypeCurrent Forecast
9/3/24 to 9/3/25		1 Month Ago
8/4/24 to 8/4/25		3 Months Ago
6/5/24 to 6/5/25		1 Year Ago
9/4/23 to 9/3/24
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
6 Buy rating(s)
6 Buy rating(s)
8 Buy rating(s)
8 Buy rating(s)
Hold
3 Hold rating(s)
3 Hold rating(s)
3 Hold rating(s)
2 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
3 Sell rating(s)
Consensus Price Target$37.60$37.80$39.17$49.50
Forecasted Upside39.54% Upside71.97% Upside79.58% Upside80.59% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Hold

GMAB Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

GMAB Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Genmab A/S Stock vs. The Competition

TypeGenmab A/SMedical CompaniesS&P 500
Consensus Rating Score
2.64
2.78
2.53
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside40.93% Upside16,147.07% Upside11.17% Upside
News Sentiment Rating
Positive News

See Recent GMAB News
Positive News
Positive News
Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
8/19/2025Zacks Research
0 of 5 stars		 DowngradeStrong-Buy ➝ Hold
8/15/2025HC Wainwright
1 of 5 stars		Raghuram Selvaraju
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost TargetBuy ➝ Buy$35.00 ➝ $36.00+56.66%
7/8/2025Truist Financial
3 of 5 stars		Asthika Goonewardene
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost TargetBuy ➝ Buy$45.00 ➝ $46.00+115.71%
4/1/2025Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating		J. Smith
Subscribe to MarketBeat All Access for the recommendation accuracy rating		DowngradeMarket Perform ➝ Underperform
3/11/2025William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Matt Phipps
Subscribe to MarketBeat All Access for the recommendation accuracy rating		UpgradeMarket Perform ➝ Outperform
2/13/2025Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating		J. Chang
Subscribe to MarketBeat All Access for the recommendation accuracy rating		UpgradeHold ➝ Strong-Buy
2/13/2025Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Jonathan Chang
Subscribe to MarketBeat All Access for the recommendation accuracy rating		UpgradeMarket Perform ➝ Outperform$27.00+37.13%
2/11/2025BNP Paribas
Subscribe to MarketBeat All Access for the recommendation accuracy rating		V. Floc'h
Subscribe to MarketBeat All Access for the recommendation accuracy rating		UpgradeStrong Sell ➝ Hold
11/8/2024BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingOutperform ➝ Outperform$46.00 ➝ $48.00+110.25%
10/8/2024Redburn Atlantic
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Q. Ding
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated CoverageBuy
9/11/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingEqual Weight ➝ Equal Weight$31.00 ➝ $31.00+15.63%
8/20/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingOverweight ➝ Neutral
7/15/2024Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating		A. Campbell
Subscribe to MarketBeat All Access for the recommendation accuracy rating		UpgradeSector Perform ➝ Outperform
6/27/2024BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetBuy ➝ Buy$46.00 ➝ $47.00+83.09%
1/22/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeNeutral ➝ Sell
12/6/2023UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 UpgradeNeutral ➝ Buy
11/10/2023Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 UpgradeHold ➝ Buy
11/8/2023DNB Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 UpgradeSell ➝ Buy
10/12/2023Nordea Equity Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeBuy ➝ Hold

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 03:27 PM ET.


Should I Buy Genmab A/S Stock? GMAB Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, September 2, 2025. Please send any questions or comments about these Genmab A/S pros and cons to contact@marketbeat.com.

Genmab A/S
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Genmab A/S:

  • Recent earnings reports indicate strong performance, with earnings per share surpassing consensus estimates, suggesting robust financial health.
  • The stock has a favorable consensus rating of "Moderate Buy" from analysts, indicating positive sentiment in the market.
  • Current stock price is around $22.91, reflecting a stable position in the market and potential for growth.
  • Analysts have projected increasing earnings per share for the upcoming years, indicating expected growth in profitability.
  • Institutional interest is strong, with several firms increasing their stakes, which often signals confidence in the company's future performance.

Genmab A/S
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Genmab A/S for these reasons:

  • The company reported revenue that fell short of analysts' expectations, which may raise concerns about its sales performance.
  • Despite positive earnings, the stock has experienced fluctuations, indicating potential volatility that could affect investor returns.
  • There is a mix of ratings from analysts, with some holding a sell or hold rating, suggesting uncertainty in the stock's future performance.
  • Recent selling by institutional investors, such as Natixis Advisors LLC, may indicate a lack of confidence among some large stakeholders.
  • The stock's price target from analysts is significantly higher than the current price, which may suggest that the market has not fully recognized its potential yet.

GMAB Forecast - Frequently Asked Questions

According to the research reports of 11 Wall Street equities research analysts, the average twelve-month stock price forecast for Genmab A/S is $37.60, with a high forecast of $48.00 and a low forecast of $27.00.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genmab A/S in the last year. There is currently 1 sell rating, 3 hold ratings, 6 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" GMAB shares.

According to analysts, Genmab A/S's stock has a predicted upside of 39.54% based on their 12-month stock forecasts.

Over the previous 90 days, Genmab A/S's stock had 1 downgrade by analysts.

Genmab A/S has been rated by research analysts at HC Wainwright, Truist Financial, and Zacks Research in the past 90 days.

Analysts like Genmab A/S less than other "medical" companies. The consensus rating score for Genmab A/S is 2.64 while the average consensus rating score for "medical" companies is 2.78. Learn more on how GMAB compares to other companies.

Related Companies
Today's Ratings
Top-Rated Stocks
More Ratings Tools

This page (NASDAQ:GMAB) was last updated on 9/3/2025 by MarketBeat.com Staff
From Our Partners
How “Trump’s New Dollar” Could Impact Your Wealth
President Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...
Brownstone Research | Sponsoredtc pixel
Forget Tesla — This Tiny AI Stock Is Musk’s Real Play
While Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...
Behind the Markets | Sponsoredtc pixel
What's the Best Way to Lower RMD Taxes?
Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...
SmartAsset | Sponsoredtc pixel
This Coin Could Explode, and it’s Hiding in Plain Sight!
The #1 coin with skyrocket potential right now... Sometimes the biggest opportunities are hiding in plain s...
Crypto 101 Media | Sponsoredtc pixel
What Steve Bannon revealed about Trump’s gold play
A Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...
Reagan Gold Group | Sponsoredtc pixel
Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...
American Alternative | Sponsoredtc pixel
Warren Buffett Issues Cryptic Warning on U.S. Dollar
Imagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...
Banyan Hill Publishing | Sponsoredtc pixel
Google did what!?!?
A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...
Stansberry Research | Sponsoredtc pixel